HK1106534A1 - Proteasome inhibitors and methods of using the same - Google Patents
Proteasome inhibitors and methods of using the sameInfo
- Publication number
- HK1106534A1 HK1106534A1 HK07112239.9A HK07112239A HK1106534A1 HK 1106534 A1 HK1106534 A1 HK 1106534A1 HK 07112239 A HK07112239 A HK 07112239A HK 1106534 A1 HK1106534 A1 HK 1106534A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- same
- proteasome inhibitors
- compositions
- proteasome activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65237005P | 2005-02-11 | 2005-02-11 | |
US11/351,193 US7468383B2 (en) | 2005-02-11 | 2006-02-09 | Proteasome inhibitors and methods of using the same |
PCT/US2006/004664 WO2006086600A1 (en) | 2005-02-11 | 2006-02-10 | Proteasome inhibitors and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1106534A1 true HK1106534A1 (en) | 2008-03-14 |
Family
ID=36579482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07112239.9A HK1106534A1 (en) | 2005-02-11 | 2007-11-09 | Proteasome inhibitors and methods of using the same |
Country Status (20)
Country | Link |
---|---|
US (2) | US7468383B2 (xx) |
EP (1) | EP1846424B1 (xx) |
JP (1) | JP2008530108A (xx) |
AT (1) | ATE456571T1 (xx) |
AU (1) | AU2006213814B2 (xx) |
CA (1) | CA2597273C (xx) |
CY (1) | CY1109985T1 (xx) |
DE (1) | DE602006012013D1 (xx) |
DK (1) | DK1846424T3 (xx) |
ES (1) | ES2339698T3 (xx) |
HK (1) | HK1106534A1 (xx) |
IL (1) | IL184678A (xx) |
MX (1) | MX2007009664A (xx) |
MY (1) | MY147921A (xx) |
NZ (1) | NZ560607A (xx) |
PL (1) | PL1846424T3 (xx) |
PT (1) | PT1846424E (xx) |
SI (1) | SI1846424T1 (xx) |
TW (1) | TWI367886B (xx) |
WO (1) | WO2006086600A1 (xx) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007011760A2 (en) * | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
DK2623113T3 (en) | 2005-11-09 | 2017-07-17 | Onyx Therapeutics Inc | Enzyme inhibition compound |
RU2450016C2 (ru) | 2006-06-19 | 2012-05-10 | Протеоликс, Инк. | Пептидные эпоксикетоны для ингибирования протеасомы |
EP2044055A4 (en) * | 2006-07-21 | 2011-03-23 | Takeda Pharmaceutical | amide compounds |
CN105837608B (zh) * | 2007-08-06 | 2018-06-08 | 米伦纽姆医药公司 | 蛋白酶体抑制剂及其组合物和用途 |
US20110118274A1 (en) * | 2007-08-23 | 2011-05-19 | Cornell Research Foundation, Inc. | Proteasome inhibitors and their use in treating pathogen infection and cancer |
PT2207791T (pt) | 2007-10-04 | 2016-07-12 | Onyx Therapeutics Inc | Inibidores da epoxi cetona protease de péptido cristalino e a síntese de ceto-epóxidos de aminoácidos |
EP2212334B1 (en) * | 2007-10-16 | 2012-08-15 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
EP2088205A1 (en) | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: A diagnosis marker and therapeutic target of chronic rejection. |
EA201500431A1 (ru) | 2008-06-17 | 2015-11-30 | Милленниум Фармасьютикалз, Инк. | Соединения боронатного эфира и его фармацевтические составы |
MX2011001349A (es) * | 2008-08-04 | 2011-08-17 | Chidi Inc | Ciertos inhibidores de quinurenin-3-monooxigenasa, composiciones farmaceuticas y metodos para su uso. |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
KR20110073584A (ko) | 2008-10-21 | 2011-06-29 | 오닉스 세라퓨틱스, 인크. | 펩티드 에폭시케톤과의 병용 요법 |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
EP2498793B1 (en) | 2009-11-13 | 2019-07-10 | Onyx Therapeutics, Inc. | Oprozomib for use in metastasis suppression |
CA2785300A1 (en) | 2009-12-22 | 2011-07-21 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
CN102811620B (zh) | 2010-01-25 | 2015-03-25 | Chdi基金会股份有限公司 | 一些犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法 |
BR112012022060A2 (pt) | 2010-03-01 | 2018-05-08 | Onyx Therapeutics Inc | composto para a inibição de imunoproteassoma |
US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
EP2627636B1 (en) | 2010-10-14 | 2015-09-02 | Synthon BV | Process for making bortezomib and the intermediates for the process |
KR102027287B1 (ko) | 2011-08-30 | 2019-10-01 | 씨에이치디아이 파운데이션, 인코포레이티드 | 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법 |
BR112014004845A2 (pt) | 2011-08-30 | 2017-04-04 | Chdi Foundation Inc | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada |
WO2014011695A2 (en) | 2012-07-09 | 2014-01-16 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
WO2014072985A1 (en) * | 2012-11-06 | 2014-05-15 | Natco Pharma Limited | Novel boronic acid derivatives as anti cancer agents |
US9493439B1 (en) | 2014-04-07 | 2016-11-15 | University Of Kentucky Research Foundation | Proteasome inhibitors |
CA2944565C (en) * | 2014-04-08 | 2022-11-29 | Neurovive Pharmaceutical Ab | Novel cell-permeable succinate compounds |
AU2015264272A1 (en) | 2014-05-20 | 2016-11-24 | Millennium Pharmaceuticals, Inc. | Boron-containing proteasome inhibitors for use after primary cancer therapy |
ES2747633T3 (es) | 2014-07-17 | 2020-03-11 | Chdi Foundation Inc | Combinación de inhibidor KMO 6-(3-cloro-4-ciclopropoxifenilo)pirimidina-4-ácido carboxílico con un agente antiviral para el tratamiento de trastornos neurológicos relacionados con VIH |
US11014943B2 (en) * | 2017-02-28 | 2021-05-25 | Chia Tai Tianqing Pharmaceutical Group Go., Ltd. | Azetidine derivative |
GB201808149D0 (en) | 2018-05-18 | 2018-07-11 | Univ Court Univ Of Glasgow | Protected amino acids |
CN115772188A (zh) * | 2018-08-02 | 2023-03-10 | 正大天晴药业集团股份有限公司 | 氮杂环丁烷衍生物的硼酸酯 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3301354A1 (de) | 1983-01-18 | 1984-07-19 | Matth. Hohner Ag, 7218 Trossingen | Elektronisches musikinstrument |
US4537773A (en) * | 1983-12-05 | 1985-08-27 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid derivatives |
US4499082A (en) * | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US5250720A (en) * | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
US5242904A (en) * | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
EP0315574A3 (de) * | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
WO1989009225A1 (en) | 1988-03-28 | 1989-10-05 | The Regents Of The University Of California | Nerve growth factor peptides |
US5023236A (en) * | 1988-04-07 | 1991-06-11 | Corvas, Inc. | Factor VII/VIIA active site inhibitors |
US5159060A (en) * | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US5106948A (en) * | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US4963655A (en) * | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
DE3827340A1 (de) | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
WO1991013904A1 (en) | 1990-03-05 | 1991-09-19 | Cephalon, Inc. | Chymotrypsin-like proteases and their inhibitors |
ES2098484T3 (es) * | 1992-08-14 | 1997-05-01 | Procter & Gamble | Detergentes liquidos que contienen un acido alfa-amino-boronico. |
EP0684829A4 (en) | 1993-02-10 | 1997-05-21 | Harvard College | THE ROLE OF ATP-UBIQUITIN-DEPENDENT PROTEOLYSIS IN MHC-1 DEPENDENT ANTIGENT PRESENTATION AND RELATED INHIBITORS. |
IL109319A0 (en) | 1993-04-27 | 1994-07-31 | Du Pont Merck Pharma | Amidino and guanidino substituted boronic acid compounds |
US5658885A (en) * | 1993-04-27 | 1997-08-19 | The Dupont Merck Pharmaceutical Company | Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes |
CA2159834A1 (en) | 1993-04-30 | 1994-11-10 | Daniel F. Veber | Thrombin inhibitors |
US5672582A (en) | 1993-04-30 | 1997-09-30 | Merck & Co., Inc. | Thrombin inhibitors |
FR2707085B1 (fr) | 1993-06-30 | 1995-08-18 | Adir | Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
EP0721449B1 (en) | 1993-10-01 | 2001-12-19 | Merrell Pharmaceuticals Inc. | Inhibitors of beta-amyloid protein production |
IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
GB9401483D0 (en) | 1994-01-26 | 1994-03-23 | Sandoz Ltd | Organic compounds |
US5693617A (en) * | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5550262A (en) * | 1994-11-14 | 1996-08-27 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US5614649A (en) * | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US5834487A (en) * | 1996-09-24 | 1998-11-10 | Cv Therapeutics | Inhibition of 26S and 20S proteasome by indanones |
ZA979327B (en) | 1996-10-18 | 1998-05-11 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease. |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
US6096778A (en) * | 1997-10-07 | 2000-08-01 | Cephalon, Inc. | α-ketoamide multicatalytic protease inhibitors |
US20010012854A1 (en) * | 1997-12-16 | 2001-08-09 | Robert Siman | Multicatalytic protease inhibitors for use as anti-tumor agents |
US6075150A (en) * | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
GB9806815D0 (en) * | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
EP0995757A3 (en) | 1998-08-26 | 2002-05-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bivalent inhibitors of the proteasome |
KR20010080267A (ko) | 1998-10-20 | 2001-08-22 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 프로테아솜 억제제 약물 작용을 모니터링하는 방법 |
EP1053750A1 (en) | 1999-04-22 | 2000-11-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis) |
ATE270268T1 (de) | 1999-04-27 | 2004-07-15 | Novartis Pharma Gmbh | 2,4-diamino-3-hydroxycarboxylsäurederivate als proteasome inhibitoren |
SE9901573D0 (sv) | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
AU5920400A (en) | 1999-07-07 | 2001-01-22 | Du Pont Pharmaceuticals Company | Cell-based assay systems for examining hcv ns3 protease activity |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
AU7832000A (en) | 1999-09-23 | 2001-04-24 | Washington University | Compounds directed against pilus biogenesis and activity in pathogenic bacteria;methods and compositions for synthesis thereof |
EP1477180A1 (en) | 1999-10-20 | 2004-11-17 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone and hair growth |
HUP0303358A3 (en) | 2000-07-21 | 2005-10-28 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them |
CA2425632A1 (en) | 2000-10-12 | 2002-04-18 | Viromics Gmbh | Agents for the treatment of viral infections |
ES2571219T3 (es) | 2001-01-25 | 2016-05-24 | The United States Of America Represented By The Secretary Dept Of Health And Human Services | Formulación de compuestos de ácido borónico |
IL158136A0 (en) | 2001-04-09 | 2004-03-28 | Method for identification of proteins from intracellular bacteria | |
WO2002094857A1 (en) | 2001-05-23 | 2002-11-28 | The Curators Of The University Of Missouri | Inverse solid phase synthesis of peptides |
US6933290B2 (en) | 2001-05-30 | 2005-08-23 | Novartis Ag | 2-{N-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl}-amino}-alkylboronic acid derivatives |
KR100399359B1 (ko) * | 2001-07-07 | 2003-09-26 | 삼성전자주식회사 | 전하 펌프 회로 |
WO2003015706A2 (en) | 2001-08-16 | 2003-02-27 | Washington State University Research Foundation | Borinic acid protease inhibitors |
WO2003033507A1 (fr) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant |
JP4412586B2 (ja) * | 2002-01-08 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 |
US20060237868A1 (en) | 2003-08-13 | 2006-10-26 | Seiko Precision Inc. | Method and device for manufacturing card |
US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
EP2178888B1 (en) | 2007-08-06 | 2012-07-04 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
-
2006
- 2006-02-09 US US11/351,193 patent/US7468383B2/en not_active Expired - Fee Related
- 2006-02-10 EP EP06734698A patent/EP1846424B1/en not_active Not-in-force
- 2006-02-10 SI SI200630615T patent/SI1846424T1/sl unknown
- 2006-02-10 AU AU2006213814A patent/AU2006213814B2/en not_active Ceased
- 2006-02-10 CA CA2597273A patent/CA2597273C/en not_active Expired - Fee Related
- 2006-02-10 AT AT06734698T patent/ATE456571T1/de active
- 2006-02-10 MY MYPI20060567A patent/MY147921A/en unknown
- 2006-02-10 JP JP2007555228A patent/JP2008530108A/ja active Pending
- 2006-02-10 MX MX2007009664A patent/MX2007009664A/es active IP Right Grant
- 2006-02-10 ES ES06734698T patent/ES2339698T3/es active Active
- 2006-02-10 DE DE602006012013T patent/DE602006012013D1/de active Active
- 2006-02-10 PT PT06734698T patent/PT1846424E/pt unknown
- 2006-02-10 TW TW095104473A patent/TWI367886B/zh not_active IP Right Cessation
- 2006-02-10 NZ NZ560607A patent/NZ560607A/en not_active IP Right Cessation
- 2006-02-10 WO PCT/US2006/004664 patent/WO2006086600A1/en active Application Filing
- 2006-02-10 DK DK06734698.1T patent/DK1846424T3/da active
- 2006-02-10 PL PL06734698T patent/PL1846424T3/pl unknown
-
2007
- 2007-07-17 IL IL184678A patent/IL184678A/en not_active IP Right Cessation
- 2007-11-09 HK HK07112239.9A patent/HK1106534A1/xx not_active IP Right Cessation
-
2008
- 2008-11-06 US US12/265,998 patent/US8283367B2/en not_active Expired - Fee Related
-
2010
- 2010-04-27 CY CY20101100375T patent/CY1109985T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US20060189806A1 (en) | 2006-08-24 |
US8283367B2 (en) | 2012-10-09 |
ES2339698T3 (es) | 2010-05-24 |
MY147921A (en) | 2013-02-15 |
JP2008530108A (ja) | 2008-08-07 |
CA2597273A1 (en) | 2006-08-17 |
WO2006086600A1 (en) | 2006-08-17 |
IL184678A0 (en) | 2007-12-03 |
CY1109985T1 (el) | 2014-09-10 |
DE602006012013D1 (de) | 2010-03-18 |
US20090075936A1 (en) | 2009-03-19 |
TWI367886B (en) | 2012-07-11 |
NZ560607A (en) | 2009-11-27 |
US7468383B2 (en) | 2008-12-23 |
AU2006213814B2 (en) | 2011-10-13 |
PL1846424T3 (pl) | 2010-06-30 |
TW200640936A (en) | 2006-12-01 |
MX2007009664A (es) | 2007-09-26 |
SI1846424T1 (sl) | 2010-05-31 |
DK1846424T3 (da) | 2010-05-17 |
AU2006213814A1 (en) | 2006-08-17 |
CA2597273C (en) | 2013-12-17 |
IL184678A (en) | 2012-05-31 |
EP1846424B1 (en) | 2010-01-27 |
ATE456571T1 (de) | 2010-02-15 |
PT1846424E (pt) | 2010-04-15 |
EP1846424A1 (en) | 2007-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI367886B (en) | Proteasome inhibitors and methods of using the same | |
HK1091839A1 (en) | Proteasome inhibitors and methods of using the same | |
HK1089153A1 (en) | Proteasome inhibitors and methods of using the same | |
PH12014500053A1 (en) | Proteasome inhibitors | |
MY192255A (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
WO2012037155A3 (en) | Tyrosine kinase inhibitors | |
MY166653A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
MY162518A (en) | Proteasome inhibitors and methods of using the same | |
MY180594A (en) | Proteasome inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180210 |